E-Mail
OAK BROOK, Ill. - Breast cancer death rates have stopped declining for women in the U.S. younger than age 40, ending a trend that existed from 1987 to 2010, according to a new study in
Radiology. Researchers expressed hope that the findings would raise awareness of breast cancer in younger women and spur research into the causes behind the change.
Breast cancer is the most common non-skin cancer and the second most common cause of cancer deaths in women in the U.S., accounting for 30% of all cancers in women. Although most invasive breast cancers occur in women age 40 years and older, 4% to 5% of cases happen in women younger than 40 years.
This article is a collaboration between MedPage Today and:
Almost 40% of progressive, advanced gastrointestinal (GI) tumors with mismatch repair deficiency (dMMR) responded to the investigational anti-PD-1 agent dostarlimab, according to a preliminary clinical trial.
Overall, 38.7% of 106 patients responded to single-agent treatment with monoclonal antibody, including 36.2% of colorectal cancers (CRC) and 43.2% of all other tumors, which were primarily GI in origin. About three-fourths of patients had some degree of tumor shrinkage. During a median follow-up exceeding 1 year, median duration of response had yet to be reached.
Dostarlimab was well tolerated, as fewer than 10% of patients had ≥3 treatment-related adverse events (TRAEs), reported Thierry Andre, MD, of Sorbonne University and Saint-Antoine Hospital in Paris, at the Gastrointestinal Cancers Symposium virtual meeting.
This article is a collaboration between MedPage Today and:
Adding a PD-1 inhibitor to neoadjuvant chemotherapy and radiotherapy failed to improve a rectal cancer-specific surrogate for survival in patients with locally advanced disease, a randomized trial showed.
The addition of pembrolizumab (Keytruda) improved the mean neoadjuvant rectal (NAR) score by 2.55 points versus conventional treatment with neoadjuvant FOLFOX chemotherapy followed by chemoradiation (CRT) with capecitabine. The difference did not meet the prespecified improvement target, and key secondary and exploratory endpoints also did not improve significantly.
The pembrolizumab arm also had more grade ≥3 adverse events (AEs), reported Osama Rahma, MD, of NRG Oncology and the Dana-Farber Cancer Institute in Boston, at the Gastrointestinal Cancers Symposium virtual meeting.
Expert panel votes FDA SHOULD give Moderna s COVID-19 vaccine emergency approval amid hopes the U.S will soon have a second shot to help get 20 million Americans vaccinated by the end of 2020
A panel of FDA experts voted that the agency should approve Moderna s coronavirus vaccine and recommend whether the shot should be approved
With their endorsement, Moderna s shot will almost certainly get emergency approval tonight or tomorrow
Two people in Moderna s trial had severe allergic reactions: one who got a placebo, and a vaccine recipient who had anaphylactic shock 63 days later
Moderna determined neither were linked to the shot, and allergic reactions are generally immediate, not months later